Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial - The Lancet Diabetes & Endocrinology
Por um escritor misterioso
Descrição
Rosuvastatin in the Primary Prevention of Cardiovascular Disease
Statins improve Graves' orbitopathy in active eye disease with
PDF) Sirolimus as a second-line treatment for Graves' orbitopathy
Current and Emerging Treatment Strategies for Graves' Orbitopathy
Proposal for Standardization of Primary and Secondary Outcomes in
Effect of dapagliflozin on the rate of decline in kidney function
Effect of dapagliflozin on the rate of decline in kidney function
Recent advances in graves ophthalmopathy medical therapy: a
Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and
Frontiers Effects of Non-statin Lipid-Modifying Agents on
Management of Thyroid Eye Disease: A Consensus Statement by the
The effects of lowering LDL cholesterol with simvastatin plus
American Thyroid Association - Our look at the STAGO trial: What's
de
por adulto (o preço varia de acordo com o tamanho do grupo)
